Given a document, find the main entity about whom the author is writing. Write the full name if mentioned in the text. Note that URLs in the text have been replaced with [Link].

The Pretenders surge through their 1981 track "Talk of the Town" in a preview of their upcoming Austin City Limits episode  which premieres Saturday  October 14th.  Chrissie Hynde and James Walbourne  form a wall of rippling guitar chords on the dreamy Pretenders II track.
In another exclusive clip of  their  debut ACL appearance  the quintet perform "I Hate Myself" from their Dan Auerbach-produced 2016 LP  Alone. Over a static drum beat  moaning pedal-steel and woozy tremolo bar drone   Hynde  berates  herself  by sneering the song title over and over.
Related The Pretenders Ain't Sobbing  Chrissie Hynde  on  her  early days as a music critic  being a woman on the road  and almost losing  her  virginity to  Ron Wood
 Hynde  also praised Auerbach for his production and laid-back spirit during the recording of Alone. "I see it as a Dan Auerbach album "  she  admitted. "In my heart of hearts  that's how I see that album. It's more like I guested with him. But of course I'm very happy to take the credit. He's the producer  and that's just the way it has to be."
Chrissie Hynde

On Tuesday  fashion house Gucci dipped into the culinary scene with the luxe Gucci Osteria  a green-walled  50-seat restaurant nestled inside the new Gucci Garden  an experiential museum-retail concept in the historic heart of Florence  Italy.  The chef  is  Massimo Bottura   the Modena-based proprietor of three-Michelin-starred Osteria Francescana  in 2016 named the best restaurant in the world.
Now fully open to the public  the menu  glimpsed here  includes the parade of pasta one expects from  Bottura  considering Osteria Francescanaâs carbo-loaded cameo on the Netflix show Master of None.
Visitors can scarf down decadent plates of golden Parmigiano-Reggiano-enriched tortellini  buttery cacio e pepe  and creamy mushroom risotto. But the menu evidently has a sense of humor  too  offering high-end interpretations of a hot dog  a burger (fun fact:  Bottura  loves Shake Shack)  and for dessert  a piÃ±a colada. There are also a fair number of dishes inspired by Botturaâs world travels  including Peruvian tostadas and Asian-tinged buns stuffed with fatty pork belly.
Main dishes are priced from 20 to 30 euros ($24-$36) eachâthis is Gucci  after all. âHaute couture and haute cuisine are a recipe made in heaven â  Bottura  told reporters. Not for nothing  Gucci Chief Executive Officer Marco Bizzarri and Bottura are childhood friends as well.
Massimo Bottura

PARIS/LONDON (Reuters) - French drugmaker Sanofi has agreed to buy  Belgian biotech company Ablynx  for 3.9 billion euros ($4.8 billion)  beating Novo Nordisk and marking its second big deal this month after buying Bioverativ.
The deal is a further sign of accelerating merger and acquisition (M&A) activity in the global biotech sector and comes after  Ablynx  rejected a 2.6 billion euro offer from Denmark’s Novo Nordisk.
Sanofi said on Monday it would pay 45 euros per share in cash for Ablynx  a premium of 21 percent over its closing price on Friday - and more than double the price before Novo went public with its initial bid.
Novo Nordisk conceded defeat  saying it did not intend to make a revised offer for Ablynx  which is developing a prized experimental drug for a rare blood disorder.
Sanofi said  Ablynx  would boost long-term value for  its  shareholders  while the takeover was expected to have a neutral impact on Sanofi’s business earnings per share (EPS) in 2018 and 2019.
Sanofi is already one of  Ablynx ’s big pharma partners  after striking a deal in July 2017 to find new treatments for inflammatory diseases.
By buying the company outright it will now get access to  Ablynx ’s most promising asset  the experimental drug caplacizumab for treating the rare bleeding disorder acquired thrombotic thrombocytopenic purpura.
Sanofi will be able to use its existing infrastructure and the recently acquired platform from Bioverativ to help to commercialize caplacizumab. It will also benefit from some of the other drugs  Ablynx  is working on  such as an infant anti-viral treatment  that would not have fitted within Novo Nordisk.
Berenberg analysts said  Ablynx  was a good fit but they estimated the deal would generate no more than a 4 percent return on invested capital  assuming caplacizumab sales of around 400 million euros by 2023.
The Danish group has sat out previous rounds of M&A in the drugs sector to focus on its core diabetes business but it now needs to find new products for its struggling smaller biopharmaceutical unit  where Ablynx would have been a good fit.
Morgan Stanley and Lazard advised Sanofi on the deal while JP Morgan advised Ablynx.

Ablynx